Other

Defined Benefit Plan, Expected Gross Prescription Drug Subsidy Receipts

Caterpillar Defined Benefit Plan, Expected Gross Prescription Drug Subsidy Receipts decreased by 8.7% to $42.00M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Defined Benefit Plan, Expected Gross Prescription Drug Subsidy Receipts shows a downward trend with a -5.5% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ4 2025
Metric ID: other_defined_benefit_plan_expected_gross_prescription_d_94f6c2

Historical Data

3 periods
 Q4 '23Q4 '24Q4 '25
Value$47.00M$46.00M$42.00M
QoQ Change—-2.1%-8.7%
YoY Change—-2.1%-8.7%
Range$42.00M – $47.00M
Avg YoY Growth-5.4%
Median YoY Growth-5.4%
Current Streak2+ quarters decline

Frequently Asked Questions

What is Caterpillar's defined benefit plan, expected gross prescription drug subsidy receipts?
Caterpillar (CAT) reported defined benefit plan, expected gross prescription drug subsidy receipts of $42.00M in Q4 2025.
What is the long-term trend for Caterpillar's defined benefit plan, expected gross prescription drug subsidy receipts?
Over 2 years (2023 to 2025), Caterpillar's defined benefit plan, expected gross prescription drug subsidy receipts has grown at a -5.5% compound annual growth rate (CAGR), from $47.00M to $42.00M.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.